fda warning letters glp-1 compounding september 2025 Issues 30 to Telehealth Firms Over Misleading Compounded Marketing Why the FDA Issued 30

Several people blame weight gain or plateaued benefit on diminished activity and laxer dietary attention

Compliance with Ethics Guidelines This article is based on previously conducted studies and is not a new study with human participants or animals

FDA Cracks Down on Deceptive Drug AdvertisingA Vital Reminder for Medical Device Industry The FDA has just launched a sweeping enforcement effort targeting misleading direct-to-consumer pharmaceutical advertising, issuing approximately 100 cease-and-desist letters and thousands of notifications aimed at ensuring transparency and accuracy in drug promotion

portfolio built specifically for GLP-1 users